8-K: Brainstorm Cell Therapeutics Secures $1M Private Placement

Brainstorm Cell Therapeutics Inc. has entered into a $1 million private placement agreement to sell common stock and warrants for working capital.

Summary

• Brainstorm Cell Therapeutics Inc. (BCLI) entered into a Securities Purchase Agreement on February 9, 2026, for a private placement with an accredited investor.
• The aggregate subscription amount is $1,000,000, to be completed in two closings of $500,000 each.
• The first closing occurred on February 9, 2026, and the second closing is scheduled 30 days thereafter.
• The purchase price for common stock is $0.60 per share.
• Pre-funded warrants are offered at $0.60 less $0.0005 per share, with an exercise price of $0.00005 per share.
• Common stock purchase warrants will be issued, exercisable for 120% of the total shares and pre-funded warrants purchased, with an exercise price of $1.00 per share and a five-year term.
• The investor can elect to receive pre-funded warrants to manage beneficial ownership limitations of 4.99% (or 9.99% at election).
• The net proceeds from the sale will be used for working capital purposes.
• The company committed to filing a registration statement for the resale of these securities within 45 calendar days and to use commercially reasonable efforts to have it effective within 181 days.
• The company will seek stockholder approval for the issuance of warrant shares within 90 days of the first closing date, and every 90 days thereafter until obtained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive development. While the capital raise addresses immediate working capital needs, the dilutive nature of the offering and the need for shareholder approval for warrant shares introduce elements of uncertainty and potential downward pressure on the stock.

Positives

• Secured $1,000,000 in capital through a private placement, providing funds for working capital.
• The structure includes pre-funded warrants and beneficial ownership blockers, which can accommodate institutional investors while managing ownership thresholds.
• Commitment to file a registration statement for resale, offering a path to liquidity for investors.

Negatives

• The issuance of common stock, pre-funded warrants, and common warrants will result in dilution for existing shareholders.
• The common warrants are exercisable for 120% of the purchased shares and pre-funded warrants, indicating significant potential future dilution.
• The exercise price of the common warrants ($1.00) is higher than the initial purchase price of common stock ($0.60), but still represents a potential dilutive event if exercised.
• The company acknowledges that hedging activities by purchasers, including short sales, could negatively impact the market price of its publicly-traded securities.

Risks

• The securities (common stock, pre-funded warrants, common warrants) have not been registered and are subject to resale restrictions under the Securities Act of 1933, as amended, and applicable state securities laws.
• Failure to maintain current public information requirements under Rule 144(c) could result in liquidated damages payable to purchasers.
• Failure to timely deliver warrant shares upon exercise could lead to liquidated damages ($10-$20 per Trading Day per $1,000 of Warrant Shares) and rescission rights for the holder.
• The company acknowledges that the issuance of the securities may result in substantial dilution of the outstanding shares of common stock.
• The company needs to obtain stockholder approval for the issuance of all warrant shares, and failure to do so could impact the transaction terms or the company's ability to fulfill its obligations.

Future Outlook

The company plans to use the net proceeds for working capital. It is committed to filing a registration statement for the resale of the issued securities within 45 calendar days and aims for it to become effective within 181 days. The company will also seek stockholder approval for the warrant shares, with meetings scheduled every 90 days until approval is obtained, indicating a clear path for future capital deployment and investor liquidity.

Management Comments

• Chaim Lebovits, President and Chief Executive Officer, signed the Form 8-K.

Industry Context

StockSavvy.ai notes that private placements with warrants are a common financing mechanism for smaller, often development-stage, biotechnology companies like Brainstorm Cell Therapeutics. This structure allows companies to raise immediate capital while offering investors additional upside potential through warrants. The beneficial ownership limitations and the use of pre-funded warrants are typical features designed to accommodate institutional investors and manage regulatory thresholds. The need for shareholder approval for the warrant shares is a standard corporate governance practice for certain equity issuances, particularly when they could be significantly dilutive.

Comparison to Industry Standards

• The pricing of $0.60 per share and a common warrant exercise price of $1.00, along with 120% warrant coverage, is generally within the range seen in private placements for small-cap biotech companies, reflecting the inherent risk and the need to incentivize investors.
• The beneficial ownership limitation of 4.99% (or 9.99% at investor election) is a standard provision in such deals, allowing investors to manage their reporting obligations under Section 13(d) of the Exchange Act.
• The commitment to file a resale registration statement within 45 days and aim for effectiveness within 181 days is a common timeline for providing liquidity to private placement investors, comparable to similar transactions by companies like XBiotech Inc. or Athersys, Inc. in their earlier financing rounds.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will experience dilution from the issuance of new common stock and the potential exercise of warrants. The stock price may be negatively impacted by the capital raise terms and potential hedging activities by the investor.
• **Investors (Purchasers)**: Gain common stock and warrants at a discounted price, with a path to liquidity via a registration statement. They also have mechanisms to manage beneficial ownership limits.
• **Company Operations**: The capital infusion provides necessary working capital, which can support ongoing operations and strategic initiatives.

Next Steps

• Second closing of the private placement, scheduled 30 days after February 9, 2026.
• Company to file a registration statement for the resale of the securities within 45 calendar days of the agreement date.
• Company to use commercially reasonable efforts to have the registration statement declared effective within 181 days after the closing.
• Company to call a stockholder meeting within 90 days of the First Closing Date to obtain Stockholder Approval for the issuance of warrant shares.
• If Stockholder Approval is not obtained, the company will call a meeting every 90 days thereafter until approval is secured.

Key Dates

Recommendation

The capital raise provides essential working capital for Brainstorm Cell Therapeutics, which is a positive for its operational continuity. However, the significant potential for dilution from the common stock and warrants, coupled with the explicit acknowledgment of potential negative market impact from investor hedging activities, creates near-term uncertainty. The requirement for shareholder approval for the warrant shares adds another layer of risk. Investors should hold and monitor the company's progress in securing shareholder approval, the effectiveness of the registration statement, and the utilization of the new capital for tangible business advancements.

Keywords

Private Placement, Warrants, Common Stock, Pre-Funded Warrants, Capital Raise, SEC Filing, Dilution, Working Capital, Securities Purchase Agreement, BCLI